User: khushpreet Topic: Sanitation
Category: Health
5 new since Apr 20 2018 13:53 IST RSS 2.0
 
1 to 20 of 14,853    
Consuming Omega-3 Fatty Acids Regularly Keeps Our Heart Healthy, Says Study 20.4.2018 NDTV News - Latest
Consuming more of Omega-3 rich foods to our diet, at least four times a week, may help in preventing the risk of heart diseases by increasing the amount of good cholesterol in our body.
Also found in: [+]
Moody's: Stable outlook for global pharmaceuticals, M&A event risk is rising 20.4.2018 General News
Among the diverse group of pharmaceutical companies rated by Moody's, those focusing on cancer drugs will see the highest EBITDA growth of more than 10%, while companies with a strong portfolio of products treating rare diseases will see solid growth in the 6%-10% range. Nevertheless, earnings growth will likely decline for a number of rated companies facing various pressure points including patent expirations, declining hepatitis C treatments and declining trends in generics and opioids.
Also found in: [+]
Glenmark gets USFDA nod for scalp and skin treatment drug 20.4.2018 General News
Glenmark Pharmaceuticals has received final approval from the US health regulator for a generic version of Temovate Topical Solution used to treat certain scalp and skin conditions. Glenmark Pharmaceuticals USA has been granted final approval by the US Food and Drug Administration (USFDA) for Clobetasol Propionate Topical Solution USP, 0.05%, the company said in a BSE filing. The approved product is the generic version of Temovate Topical Solution, 0.05%. For the 12 months period ending February 2018, Temovate Topical Solution, 0.05%, achieved annual sales of approximately USD 46.2 million, Glenmark said, citing IQVIA sales data. Glenmark said this product will be manufactured at its Baddi plant. The company's current portfolio consists of 133 products authorised for distribution at the US marketplace and 60 abbreviated new drug applications (ANDA) pending approval with the USFDA. Glenmark shares were trading 0.05 per cent lower at Rs 564.75 on the BSE.
Also found in: [+]
Delicious ways to eat mangoes this season 20.4.2018 All News-IANS Stories
From mango sandwich to a mango dessert, one can try out some delicious ways of trying this fruit so that you can make the most of it this season.
Also found in: [+]
An Ultimate Guide To Cook And Eat Prawns The Right Way 20.4.2018 NDTV Food - Latest
Prawns are an excellent source of unsaturated fats that help improve blood cholesterol levels. Just like any other fish, they are loaded with omega-3 fatty acids that your body does not produce
Also found in: [+]
Mobile app for farmers 20.4.2018 The Assam Tribune
Mobile app for farmers
Also found in: [+]
Takeda shares drop after Shire rejects $63 bln offer 20.4.2018 Reuters: Money News
TOKYO (Reuters) - Japan's Takeda Pharmaceutical Co Ltd shares fell on Friday after rare disease drug maker Shire Plc rejected its $63 billion cash-and-stock acquisition offer.
Also found in: [+]
Takeda shares down 3 percent after Shire rejects $63 billion offer 20.4.2018 General News
TOKYO (Reuters) - Japan's Takeda Pharmaceutical Co Ltd <4502.T> shares were down 3 percent in morning trading in Tokyo on Friday after rare disease drug maker Shire Plc rejected its $63 billion cash-and-stock acquisition offer.
Also found in: [+]
Takeda shares drop after Shire rejects $63 bln offer 20.4.2018 General News
TOKYO (Reuters) - Japan's Takeda Pharmaceutical Co Ltd <4502.T> shares fell on Friday after rare disease drug maker Shire Plc rejected its $63 billion cash-and-stock acquisition offer.
Also found in: [+]
Parties welcome SC order on Lokayukta 20.4.2018 Hindu: Policy & Issues
‘State govt. afraid of its corrupt administration’
Also found in: [+]
Shire rejects $63 billion Takeda bid as Allergan drops pursuit 20.4.2018 Reuters: Money News
NEW YORK/LONDON (Reuters) - Rare disease drug maker Shire Plc said on Thursday it had rejected a $63 billion cash-and-stock acquisition offer by Japan's Takeda Pharmaceutical Co Ltd , while Allergan Plc reversed course on pursuing a rival ...
Also found in: [+]
Shire rejects $63 billion Takeda bid as Allergan drops pursuit 20.4.2018 General News
NEW YORK/LONDON (Reuters) - Rare disease drug maker Shire Plc said on Thursday it had rejected a $63 billion cash-and-stock acquisition offer by Japan's Takeda Pharmaceutical Co Ltd <4502.T>, while Allergan Plc reversed course on pursuing a rival bid.
Also found in: [+]
Coconut growers in distress 19.4.2018 Hindu: Bangalore
Turning to dairy farming, garment factories
Also found in: [+]
Apple loses sheen for Kanthallur ryots 19.4.2018 Hindu: National
Climate change and pest attacks have impacted yield
Also found in: [+]
'India absent from Malaria Summit in London' 19.4.2018 All News-IANS Stories
India was conspicuous by its absence from the Malaria Summit in London alongside the 25th Commonwealth Heads of Government Meeting (CHOGM) despite having the third largest malaria cases in the world after Congo and Nigeria, those campaigning against the disease said on Thursday.
Also found in: [+]
Young adults more at risk of liver function abnormalities, says survey (April 19 is World Liver Day) 19.4.2018 General News
Owing to a sedentary lifestyle coupled with non-adherence to a balanced diet, an increasing number of young adults below 40 are facing liver function abnormalities, which if not attended to early can lead to liver diseases, finds a survey.
Also found in: [+]
Jaundice cases on the rise as summer intensifies 19.4.2018 Hindu: Home
Unhygienic water being used at mass gatherings and public functions
Also found in: [+]
The Biggest Weight Loss Myths Debunked By Celebrity Nutritionist 19.4.2018 NDTV News - Latest
If I eat fats, I will gain weight. But is that true? Celebrity Nutritionist Nmami Agarwal debunks these very popular myths around weight loss
Also found in: [+]
R. Madhavan appeals for 'dignity' to leprosy victims 19.4.2018 General News
Actor R. Madhavan, who has supported leprosy initiatives, wants victims of the skin and nerve disease to live with dignity.
Also found in: [+]
Takeda makes $61 billion bid for drugmaker Shire - sources 19.4.2018 General News
LONDON (Reuters) - Takeda Pharmaceutical has made a bid for Shire that values the London-listed drugmaker at around $61 billion, two sources with direct knowledge of the matter told Reuters.
1 to 20 of 14,853